.jpg "Intercept Pharma (NASDAQ: ICPT)")
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intercept Pharma (NASDAQ: ICPT), Nektar Therapeutics (NASDAQ: NKTR) and Pacira Pharmaceuticals (NASDAQ: PCRX).
Intercept Pharma (NASDAQ: ICPT)
In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Intercept Pharma (NASDAQ: ICPT), with a price target of $203. The company’s shares opened today at $70.87.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 8.9% and a 43.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
Currently, the analyst consensus on Intercept Pharma is Moderate Buy and the average price target is $107.33, representing a 51.4% upside.
In a report issued on May 9, Cowen & Co. also maintained a Buy rating on the stock with a $88 price target.
See today’s analyst top recommended stocks >>
Nektar Therapeutics (NASDAQ: NKTR)
In a report released today, Arlinda Lee from Canaccord Genuity reiterated a Buy rating on Nektar Therapeutics (NASDAQ: NKTR), with a price target of $94. The company’s shares opened today at $75.
According to TipRanks.com, Lee is a 3-star analyst with an average return of 4.1% and a 46.0% success rate. Lee covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Aquinox Pharmaceuticals, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Nektar Therapeutics is Strong Buy and the average price target is $107.63, representing a 43.5% upside.
In a report issued on April 26, Piper Jaffray also maintained a Buy rating on the stock with a $125 price target.
Pacira Pharmaceuticals (NASDAQ: PCRX)
Canaccord Genuity analyst Dewey Steadman maintained a Hold rating on Pacira Pharmaceuticals (NASDAQ: PCRX) today and set a price target of $34. The company’s shares opened today at $34.45.
According to TipRanks.com, Steadman is ranked 0 out of 5 stars with an average return of -6.7% and a 31.9% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Cardiome Pharma Corp, and Perrigo Company plc.
Currently, the analyst consensus on Pacira Pharmaceuticals is Moderate Buy and the average price target is $45.92, representing a 33.3% upside.
In a report issued on May 3, Mizuho Securities also reiterated a Hold rating on the stock with a $31 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
